Other Targets

Cat. No.

AT0807

CAS No.

1000676-41-4

Lirilumab

Synonyms: IPH2102

Lirilumab (IPH2102) is a monoclonal antibody targeting KIR (Killer-cell Immunoglobulin-like Receptors), demonstrating significant antitumor activity. This antibody is specifically designed for research applications focusing on leukemia and squamous cell carcinoma of the head and neck (SCCHN), providing a valuable tool for studies aimed at understanding and potentially modulating immune responses in these cancers.

Cat. No.

AT0809

CAS No.

1221901-33-2

XmAb 5592

XmAb 5592 is a humanized, Fc-engineered monoclonal antibody targeting HM1.24, designed to enhance binding affinity to FcγRIIIa and FcγRIIa receptors. This antibody facilitates increased lysis of HM1.24-specific multiple myeloma (MM) cells through both antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) in vitro. This specificity and mechanism of action make XmAb 5592 a valuable tool for research into therapeutic interventions for multiple myeloma.

Cat. No.

AT0814

Anti-ANO1/TMEM16A Antibody

The Anti-ANO1/TMEM16A Antibody is a recombinant human antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target ANO1/TMEM16A, a calcium-activated chloride channel implicated in various physiological processes. This antibody is composed of a human IgG2 heavy chain and a human kappa light chain, with an approximate molecular weight of 150 kDa. For isotype control, it is recommended to use Human IgG1 kappa, Isotype Control, to aid in distinguishing specific from non-specific binding.

Cat. No.

AT0815

Anti-Orai1 Antibody

The Anti-Orai1 Antibody is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting the Orai1 protein. This antibody is composed of a human IgG2 heavy chain and a human lambda light chain, with an approximate molecular weight of 150 kDa. For isotype control, the Human IgG2 kappa, Isotype Control is recommended. This product is essential for studies focusing on the role of Orai1 in calcium channel function and its implications in immune response and various cellular processes.

Cat. No.

AT0816

Anti-CXC-ELR Antibody

The Anti-CXC-ELR Antibody is a human-derived monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells. It specifically targets the CXC-ELR motif. This antibody is composed of a human IgG4SP heavy chain and a human kappa light chain, with an approximate molecular weight of 150 kDa. For use as an isotype control, the Human IgG4 kappa, Isotype Control is recommended. This product is ideal for research applications requiring precise targeting of the CXC-ELR motif.

Cat. No.

AT0818

Anti-TNFSF9/4-1BBL Antibody

The Anti-TNFSF9/4-1BBL Antibody is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells that specifically targets TNFSF9, also known as 4-1BBL. This antibody is comprised of a human IgG1 heavy chain and a human kappa light chain, with an estimated molecular weight of 150 kDa. For isotype control purposes, researchers should use the Human IgG1 kappa, Isotype Control. This antibody is ideal for studies focusing on the biological activities and interactions of TNFSF9/4-1BBL in immune regulation and cancer immunotherapy research.

Cat. No.

AT0829

CAS No.

2744274-17-5

Recibokibart

Recibokibart is a humanized IgG1κ monoclonal antibody specifically targeting IL1RL2. For experimental control purposes, it is recommended to use Human IgG1 kappa as the isotype control.

Cat. No.

AT0830

CAS No.

2803430-16-0

Navenibart

Navenibart is a humanized IgG1κ monoclonal antibody specifically targeting KLKB1. For experimental control purposes, it is recommended to use Human IgG1 kappa as an isotype control.

Cat. No.

AT0836

CAS No.

195189-17-4

Minretumomab

Synonyms: CC-49

Minretumomab (CC-49) is a murine monoclonal antibody that targets TAG-72 (tumor-associated glycoprotein 72), a protein frequently overexpressed in various carcinomas. This antibody is extensively utilized in the study of cancer biology and immune response mechanisms, providing valuable insights into tumor markers and the development of therapeutic strategies.

Cat. No.

AT0842

CAS No.

2749515-10-2

Lixudebart

Lixudebart is a humanized IgG1-kappa monoclonal antibody that specifically targets Claudin-1 (CLDN1). This antibody is designed for the study of CLDN1's role in tight junction integrity and its implications in various pathological conditions. Lixudebart's high specificity and affinity make it an ideal tool for detailed biochemical and cellular research applications.

Cat. No.

AT0847

CAS No.

2485020-60-6

Elarekibep

Synonyms: PRS-060; AZD1402

Elarekibep (PRS-060/AZD1402) is a potent, long-acting full antagonist of the IL-4 receptor alpha (IL-4Ra), characterized by high affinity and slow dissociation rates. This agent is specifically designed for the study of Type 2 endotype asthma, providing a valuable tool for research into the pathophysiology and potential therapeutic interventions for this condition.

Cat. No.

AT0854

Anti-MHC Class I Antibody (W6/32)

The Anti-MHC Class I Antibody (W6/32) is a chimeric mouse monoclonal antibody of the IgG2a, κ isotype, specifically designed to target human MHC Class I molecules. For accurate isotype control in experimental procedures, it is recommended to use the Mouse IgG2a kappa, Isotype Control with this antibody. This product is essential for research focusing on the immune response, antigen presentation, and cellular immunity.

Cat. No.

AT0857

CAS No.

1092658-06-4

Ensituximab

Synonyms: Anti-MUC5AC Reference Antibody (ensituximab; NEO-102

Ensituximab (NEO-102; NPC-1C) is a chimeric monoclonal IgG1 antibody designed to target a specific variant of the MUC5AC glycoprotein. This antibody exhibits high specificity for tumor-associated MUC5AC variants frequently expressed in colorectal and pancreatic cancers. Ensituximab's targeted mechanism of action makes it a valuable tool for research focused on these types of malignancies, providing potential insights into disease pathways and therapeutic approaches.

Cat. No.

AT0875

Anti-LAP Antibody

The Anti-LAP Antibody is a humanized monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically designed to target the latency-associated peptide (LAP). This antibody is composed of a human IgG2 heavy chain and a human kappa light chain, exhibiting a predicted molecular weight of approximately 150 kDa. Researchers seeking an isotype control for this antibody may utilize the Human IgG2 kappa, Isotype Control to ensure specificity and accuracy in their experimental applications. This product is ideal for use in various immunological assays to study the role and regulation of LAP in biological systems.

Cat. No.

AT0877

CAS No.

2225850-33-7

Zelminemab

Synonyms: AMG-301

Zelminemab (AMG-301) is a humanized monoclonal antibody designed to selectively inhibit the PACAP type I (PAC1) receptor. This targeted approach offers potential therapeutic applications in the modulation of pathways involved in various neurological disorders.

Cat. No.

AT0889

CAS No.

2254082-79-4

Isecarosmab

Synonyms: M-6495

Isecarosmab (M-6495) is a monoclonal antibody targeting ADAMTS with a dissociation constant (K_D) of 3.65 pM, indicative of high affinity binding. This antibody exhibits chondroprotective and anti-inflammatory properties, making it valuable in research focused on inflammatory and degenerative joint diseases. Additionally, Isecarosmab has been engineered to bind albumin, which enhances its plasma half-life, thereby potentially improving its therapeutic efficacy and stability in physiological conditions.

Cat. No.

AT0890

CAS No.

2168561-26-8

Manelimab

Synonyms: BCD-135

Manelimab is a monoclonal antibody designed to selectively inhibit programmed death-ligand 1 (PD-L1), a key molecular target involved in the suppression of the immune response, particularly in the context of tumor evasion. This antibody has potential applications in oncological research and therapeutic interventions aimed at enhancing immune system activity against various cancers.

Cat. No.

AT0894

CAS No.

2403683-24-7

Galegenimab

Synonyms: FHTR 2163; RG 6147; RO 7171009

Galegenimab, designated as FHTR 2163, RG 6147, and RO 7171009, is a monoclonal antibody fragment targeting High-temperature requirement A serine peptidase 1 (HTRA1). This antibody fragment is specifically developed for the investigation of its therapeutic potential in age-related macular degeneration (AMD). Galegenimab is utilized primarily in research settings to explore the pathological mechanisms of AMD and to assess its efficacy as a potential treatment modality.

Cat. No.

AT0901

CAS No.

1044758-60-2

Etrolizumab

Synonyms: rhuMAb Beta7; RG7413; PRO145223

Etrolizumab, also known as rhuMAb Beta7, is a gut-selective monoclonal antibody that selectively targets the β7 subunit of α4β7 and αEβ7 integrins. This antibody demonstrates high affinity binding, with dissociation constants (Ki) of 18 nM for Human α4β7 and 1.8 nM for Human αEβ7-293 integrins. Etrolizumab is primarily utilized in the research of inflammatory bowel diseases (IBD), making it a valuable tool for studies aimed at understanding and potentially treating these conditions.

Cat. No.

AT0905

Anti-SCN9a/Nav1.7 Antibody

The Anti-SCN9a/Nav1.7 Antibody is a human monoclonal antibody expressed in Chinese Hamster Ovary (CHO) cells, specifically targeting the SCN9a/Nav1.7 ion channel. This antibody comprises a human IgG1 heavy chain and a human kappa light chain, with an approximate molecular weight of 150 kDa. For experimental control purposes, the recommended isotype control is Human IgG1 kappa. This antibody is suitable for use in various biochemical and cellular research applications to study the role of the Nav1.7 channel in pain perception and other neurological functions.

Cat. No.

AT0907

CAS No.

2226393-85-5

Avdoralimab

Synonyms: IPH 5401; Anti-C5aR1 mAb

Avdoralimab (IPH 5401) is a fully human IgGκ monoclonal antibody designed to selectively target and inhibit the complement C5a receptor 1 (C5aR1). By blocking the interaction between C5aR1 and its ligand C5a, Avdoralimab effectively prevents receptor activation, offering a therapeutic strategy for the study of complement-driven inflammatory diseases and solid tumors. This antibody is pivotal for researchers focusing on the role of the complement system in pathology and the therapeutic potential of complement inhibition.

Cat. No.

AT0917

Anti-STOP1 Antibody

The Anti-STOP1 Antibody is a human monoclonal antibody derived from Chinese Hamster Ovary (CHO) cells, specifically targeting the STOP1 protein. This antibody is composed of a human IgG1 heavy chain and a human kappa light chain, exhibiting a predicted molecular weight of 150 kDa. For isotype control purposes, Human IgG1 kappa, Isotype Control is recommended. This antibody is suitable for a variety of research applications focusing on the function and regulation of the STOP1 protein.

Cat. No.

AT0922

Anti-ERG Antibody

Cat. No.

AT0923

Anti-PAR2 Antibody